Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines.

ABSTRACT:

Background

Despite the large-scale clinical application of programmed death-ligand 1 (PD-L1) monoclonal antibody, reduction in its clinical response rate has become a gradual problem. As such, use of PD-L1 monoclonal antibody in combination with other anticarcinoma drugs has been the main strategy in improving its efficacy. Interleukin 10 (IL10) is a recognized inflammatory and immunosuppressive factor. Previous studies have suggested that there is a link between PD-L1 and IL10.

Objective

This study was aimed at clarifying the relationship between PD-L1 and IL10 in liver hepatocellular carcinoma (LIHC) and whether IL10 enhances the efficacy of PD-L1 inhibitor.

Methods

Expression levels of PD-L1 and IL10 in carcinoma and adjacent tissues were tested by immunochemistry,

SUBMITTER: Qian Q 

PROVIDER: S-EPMC7381951 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature